Avant Genomics has secured over $3 million in funding to develop its Avant Source platform, which aims to automate liquid biopsy sample preparation and improve cell-free DNA recovery.
ClearNote Health will present data at DDW 2026 showing its Avantect Pancreatic Cancer Test achieved 82.6% sensitivity and 97.5% specificity in patients at elevated risk.
Amplified Sciences has received CAP accreditation for its clinical laboratory, enabling broader commercial deployment of its PanCystPro assay for pancreatic cancer risk assessment, the company announced.
The assay predicts both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More
Ultima Genomics presented data at AACR 2026 showing its ppmSeq technology detected circulating tumor DNA at low single-digit parts-per-million in a TRACERx pilot of 50 plasma samples.
Read More
TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
Read More
Labcorp has launched nationwide testing with Agilent’s FDA-approved PD-L1 IHC 22C3 pharmDx, enabling identification of patients with platinum-resistant ovarian cancer eligible for pembrolizumab immunotherapy.
Read More
A study identified microRNA patterns in blood plasma that could support noninvasive diagnosis and monitoring of the most aggressive form of brain cancer.
Read More
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
Read More
AI integrated into molecular profiling workflows identified misclassified lung cancer cases, highlighting its potential role in improving diagnostic accuracy in clinical labs.
Read More
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Read More
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More
ViewsML will present research on its AI-powered virtual immunohistochemistry platform at AACR 2026, highlighting biomarker detection from routine H&E slides without traditional staining.
Read More
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
Read More
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Read More
The tool uses digitized pathology slides to estimate how patients will respond to therapy before surgery.
Read More